Colorectal Cancer
Conditions
Brief summary
Immunotherapy improved efficacy and survival in selective patients with metastatic colorectal cancer (mCRC), however, limited data revealed the landscape of immunotherapy efficacy. What's more, potential markers have not been comprehensively evaluated to identify responding patients to further improve efficacy.The investigators conducted a single-arm study to investigate the efficacy of combination immunotherapy in patients with mCRC, and the combined regimen is determined by the physician in charge.
Interventions
DRUGCombinations
PD-1 inhibitor-based combinaiton treatment
Sponsors
First Affiliated Hospital of Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* patients who had both baseline measurable lesion(s) and at least one post-baseline radiological disease reassessment * patients with identified genomic status
Exclusion criteria
* patients who received immune monotherapy * patients who stopped treatment for any reason without identified response assessment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Durable clinical benefit | immediately after the intervention | Rate of patients who acheived CR or PR or SD that lasted more than 6 months |
Countries
China
Outcome results
None listed